John Gever is a freelance writer specializing in medicine and healthcare. His work focuses on medical specialties, with a particular emphasis on topics such as rheumatology, gene therapy, immunology, and immunotherapy. John has been featured in Knowledia, MedPage Today, and MSN.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Not enough data
John Gever's coverage primarily focuses on medical research related to autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, and osteoarthritis. He heavily relies on data in his articles. Given the nature of his work, he would likely be interested in hearing from experts who can provide insights into new research findings or clinical data related to autoimmune diseases and their treatment.
As a journalist covering scientific and healthcare topics with a strong emphasis on citing data, John may prefer sources who are actively involved in medical research or have access to significant clinical data that can support the points being made. Additionally, given the technical nature of his reporting, pitches should be tailored towards providing detailed scientific insights rather than general healthcare trends.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: John Gever
Large German study suggests it's not a specific indicator of inflammation, as once thought
John Gever Some 30% of a large general-population sample in Germany showed sacroiliac bone marrow edema (SBME) in MRI scans, a new study
Dose-response signal appears in phase II trial, and all doses are better than placebo
John Gever Enpatoran, an investigational oral drug that inhibits Toll-like receptors (TLR) 7 and 8, was superior to placebo in relieving lupus skin manifestations in a dose-finding phase II trial.
Second agent targeting BAFF and APRIL appears effective in phase III trial
John Gever Patients with immunoglobulin A (IgA) nephropathy had less protein in their urine -- a key surrogate marker for the renal impairment
Now it's up to clinicians to sort out conflicting evidence
Decision aid clarifies benefits and risks; trial shows it improved adherence
Study finds most complaints arise from other meds such as antacids and antibiotics
By: John Gever
Key Takeaways Many patients who develop rheumatoid arthritis (RA) have anti-citrullinated protein antibodies (ACPA) while early symptoms are present but before full-blown RA can be diagnosed.
